Top advances of the year: Perioperative therapy for lung cancer

被引：2

作者：

Aredo, Jacqueline V. ^{[1
]}

Wakelee, Heather A. ^{[2
]}

机构：

[1] Univ Calif San Francisco, Dept Med, San Francisco, CA USA

[2] Stanford Univ, Sch Med, Stanford Canc Inst, Div Oncol,Dept Med, 875 Blake Wilbur Dr, Stanford, CA 94305 USA

来源：

CANCER | 2024年 / 130卷 / 17期

关键词：

adjuvant; lung cancer; neoadjuvant; perioperative immunotherapy; PLUS CHEMOTHERAPY; PEMBROLIZUMAB; SURVIVAL; PLACEBO;

D O I：

10.1002/cncr.35357

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Emerging data supporting the rise of perioperative immune checkpoint inhibitors (ICIs) as a standard of care in the treatment of early stage, surgically resectable non-small cell lung cancer (NSCLC) dominated the NSCLC news in 2023. Adjuvant pembrolizumab became the second adjuvant ICI to receive US Food and Drug Administration approval in early 2023 after the 2021 approval of adjuvant atezolizumab and the 2022 approval of neoadjuvant nivolumab with chemotherapy. Subsequently in 2023, multiple phase 3 trials examining perioperative ICIs were positive and demonstrated clinically meaningful outcomes by prolonging event-free survival, improving pathologic complete response rates, and trending toward improved overall survival in most. Perioperative pembrolizumab became the first ICI to attain US Food and Drug Administration approval in this setting through the KEYNOTE-671 trial (ClinicalTrials.gov identifier NCT03425643), which also demonstrated a definitive overall survival benefit in the entire study population. However, questions remain regarding patient selection for either approach and how we can optimize biomarkers to determine who needs adjuvant therapy after surgery.

引用

页码：2897 / 2903

页数：7

共 24 条

[1]

BeiGene LTD, 2023, BEIGENE ANN PHAS 3 R

[2] CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage IIeIIIb NSCLC [J].

Cascone, T. ;

Awad, M. M. ;

Spicer, J. D. ;

He, J. ;

Lu, S. ;

Sepesi, B. ;

Tanaka, F. ;

Taube, J. M. ;

Cornelissen, R. ;

Havel, L. ;

Kuzdzal, J. ;

Petruzelka, L. B. ;

Wu, L. ;

Pujol, J. L. ;

Ito, H. ;

Erdmann, C. Coronado ;

Sathyanarayana, P. ;

Meadows-Shropshire, S. ;

Pulla, M. Provencio .

ANNALS OF ONCOLOGY, 2023, 34 :S1295-S1295

[3]

F. Hoffman-La Roche Ltd, 2022, GLOBENEWSWIRE 0609

[4] Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial [J].

Felip, E. ;

Altorki, N. ;

Zhou, C. ;

Vallieres, E. ;

Martinez-Marti, A. ;

Rittmeyer, A. ;

Chella, A. ;

Reck, M. ;

Goloborodko, O. ;

Huang, M. ;

Belleli, R. ;

McNally, V. ;

Srivastava, M. K. ;

Bennett, E. ;

Gitlitz, B. J. ;

Wakelee, H. A. .

ANNALS OF ONCOLOGY, 2023, 34 (10) :907-919

[5] Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial [J].

Felip, Enriqueta ;

Altorki, Nasser ;

Zhou, Caicun ;

Csoszi, Tibor ;

Vynnychenko, Ihor ;

Goloborodko, Oleksandr ;

Luft, Alexander ;

Akopov, Andrey ;

Martinez-Marti, Alex ;

Kenmotsu, Hirotsugu ;

Chen, Yuh-Min ;

Chella, Antonio ;

Sugawara, Shunichi ;

Voong, David ;

Wu, Fan ;

Yi, Jing ;

Deng, Yu ;

McCleland, Mark ;

Bennett, Elizabeth ;

Gitlitz, Barbara ;

Wakelee, Heather .

LANCET, 2021, 398 (10308) :1344-1357

[6] Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer [J].

Forde, Patrick M. ;

Spicer, Jonathan ;

Lu, Shun ;

Provencio, Mariano ;

Mitsudomi, Tetsuya ;

Awad, Mark M. ;

Felip, Enriqueta ;

Broderick, Stephen R. ;

Brahmer, Julie R. ;

Swanson, Scott J. ;

Kerr, Keith ;

Wang, Changli ;

Ciuleanu, Tudor-Eliade ;

Saylors, Gene B. ;

Tanaka, Fumihiro ;

Ito, Hiroyuki ;

Chen, Ke-Neng ;

Liberman, Moishe ;

Vokes, Everett E. ;

Taube, Janis M. ;

Dorange, Cecile ;

Cai, Junliang ;

Fiore, Joseph ;

Jarkowski, Anthony ;

Balli, David ;

Sausen, Mark ;

Pandya, Dimple ;

Calvet, Christophe Y. ;

Girard, Nicolas .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21) :1973-1985

[7] Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [J].

Gettinger, Scott ;

Rizvi, Naiyer A. ;

Chow, Laura Q. ;

Borghaei, Hossein ;

Brahmer, Julie ;

Ready, Neal ;

Gerber, David E. ;

Shepherd, Frances A. ;

Antonia, Scott ;

Goldman, JonathanW. ;

Juergens, Rosalyn A. ;

Laurie, Scott A. ;

Nathan, Faith E. ;

Shen, Yun ;

Harbison, Christopher T. ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) :2980-+

[8] Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer [J].

Heymach, John V. ;

Harpole, David ;

Mitsudomi, Tetsuya ;

Taube, Janis M. ;

Galffy, Gabriella ;

Hochmair, Maximilian ;

Winder, Thomas ;

Zukov, Ruslan ;

Garbaos, Gabriel ;

Gao, Shugeng ;

Kuroda, Hiroaki ;

Ostoros, Gyula ;

Tran, Tho V. ;

You, Jian ;

Lee, Kang-Yun ;

Antonuzzo, Lorenzo ;

Papai-Szekely, Zsolt ;

Akamatsu, Hiroaki ;

Biswas, Bivas ;

Spira, Alexander ;

Crawford, Jeffrey ;

Le, Ha T. ;

Aperghis, Mike ;

Doherty, Gary J. ;

Mann, Helen ;

Fouad, Tamer M. ;

Reck, Martin .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (18) :1672-1684

[9] Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis [J].

Lee, Chee Khoon ;

Man, Johnathan ;

Lord, Sally ;

Links, Matthew ;

Gebski, Val ;

Mok, Tony ;

Yang, James Chih-Hsin .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) :403-407

[10] A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC [J].

Lisberg, A. ;

Cummings, A. ;

Goldman, J. W. ;

Bornazyan, K. ;

Reese, N. ;

Wang, T. ;

Coluzzi, P. ;

Ledezma, B. ;

Mendenhall, M. ;

Hunt, J. ;

Wolf, B. ;

Jones, B. ;

Madrigal, J. ;

Horton, J. ;

Spiegel, M. ;

Carroll, J. ;

Gukasyan, J. ;

Williams, T. ;

Sauer, L. ;

Wells, C. ;

Hardy, A. ;

Linares, P. ;

Lim, C. ;

Ma, L. ;

Adame, C. ;

Garon, Edward B. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :1138-1145

← 1 2 3 →